PubMed:23952588 / 1415-1485 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T19","span":{"begin":0,"end":70},"obj":"Sentence"}],"text":"The prevalence of levodopa-induced dyskinesia in our patients was 44%."}

{"project":"LitCoin-entities","denotations":[{"id":"9351","span":{"begin":18,"end":26},"obj":"ChemicalEntity"},{"id":"9352","span":{"begin":35,"end":45},"obj":"DiseaseOrPhenotypicFeature"},{"id":"9353","span":{"begin":53,"end":61},"obj":"OrganismTaxon"}],"attributes":[{"id":"A29","pred":"db_id","subj":"9351","obj":"MESH:D007980"},{"id":"A30","pred":"db_id","subj":"9352","obj":"MESH:D004409"},{"id":"A31","pred":"db_id","subj":"9353","obj":"NCBITaxon:9606"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"The prevalence of levodopa-induced dyskinesia in our patients was 44%."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T15","span":{"begin":27,"end":34},"obj":"GeneOrGeneProduct"}],"text":"The prevalence of levodopa-induced dyskinesia in our patients was 44%."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T17","span":{"begin":35,"end":45},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A17","pred":"originalLabel","subj":"T17","obj":"D020820"}],"text":"The prevalence of levodopa-induced dyskinesia in our patients was 44%."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T17","span":{"begin":35,"end":45},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A17","pred":"ID:","subj":"T17","obj":"D020820"}],"text":"The prevalence of levodopa-induced dyskinesia in our patients was 44%."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T15","span":{"begin":35,"end":45},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A15","pred":"#label","subj":"T15","obj":"D020820"}],"text":"The prevalence of levodopa-induced dyskinesia in our patients was 44%."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T10","span":{"begin":18,"end":26},"obj":"ChemicalEntity"}],"attributes":[{"id":"A10","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_15765"}],"text":"The prevalence of levodopa-induced dyskinesia in our patients was 44%."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T5","span":{"begin":53,"end":61},"obj":"OrganismTaxon"}],"text":"The prevalence of levodopa-induced dyskinesia in our patients was 44%."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T10","span":{"begin":18,"end":26},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":35,"end":45},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T17364","span":{"begin":53,"end":61},"obj":"OrganismTaxon"}],"attributes":[{"id":"A10","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_15765"},{"id":"A15","pred":"#label","subj":"T15","obj":"D020820"}],"text":"The prevalence of levodopa-induced dyskinesia in our patients was 44%."}